Rohto Pharmaceutical Co.,Ltd. (TYO:4527)
Japan · Delayed Price · Currency is JPY | Market Cap | 534.74B +4.4% |
| Revenue (ttm) | 335.80B +13.6% |
| Net Income | 34.54B +16.8% |
| EPS | 148.61 +14.9% |
| Shares Out | 225.96M |
| PE Ratio | 15.92 |
| Forward PE | 16.05 |
| Dividend | 46.00 (1.93%) |
| Ex-Dividend Date | Mar 30, 2026 |
| Volume | 794,300 |
| Average Volume | 605,315 |
| Open | 2,357.50 |
| Previous Close | 2,387.00 |
| Day's Range | 2,333.00 - 2,379.50 |
| 52-Week Range | 1,964.50 - 2,703.00 |
| Beta | -0.47 |
| RSI | 45.42 |
| Earnings Date | May 12, 2026 |
About Rohto Pharmaceutical
Rohto Pharmaceutical Co.,Ltd. manufactures and markets pharmaceutical products, cosmetics, and functional foods worldwide. The company provides eye care products, such as eye drops, care for contact lenses, and eye wash; and facial care products comprising face wash, lotions, and creams. It also offers medicine and medicated products for skin, lip balms, sunscreens, functional cosmetics, etc.; medicine for internal use, such as digestive and herbal medicines; regenerative medicines; OTC pharmaceutical products, including ophthalmic, dermatologi... [Read more]
Financial Performance
In fiscal year 2025, Rohto Pharmaceutical's revenue was 308.63 billion, an increase of 13.95% compared to the previous year's 270.84 billion. Earnings were 31.01 billion, an increase of 0.23%.
Financial StatementsNews
Activist turns up the heat on Rohto Pharmaceutical
Activist und manager Asset Value Investors has intensified its campaign against Rohto Pharmaceutical Co, escalating a year-long effort.